Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $83.72 million. The enterprise value is $87.52 million.

Market Cap	83.72M
Enterprise Value	87.52M

Important Dates

The last earnings date was Friday, February 14, 2025, after market close.

Earnings Date	Feb 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Citius Oncology has 71.55 million shares outstanding. The number of shares has increased by 2.32% in one year.

Current Share Class	71.55M
Shares Outstanding	71.55M
Shares Change (YoY)	+2.32%
Shares Change (QoQ)	+2.64%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.29%
Float	5.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	2.03
P/TBV Ratio	2.03
P/FCF Ratio	662.56
P/OCF Ratio	662.56
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	692.63

Financial Position

The company has a current ratio of 0.39, with a Debt / Equity ratio of 0.09.

Current Ratio	0.39
Quick Ratio	n/a
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	30.08
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -72.11% and return on invested capital (ROIC) is -41.26%.

Return on Equity (ROE)	-72.11%
Return on Assets (ROA)	-20.24%
Return on Invested Capital (ROIC)	-41.26%
Return on Capital Employed (ROCE)	-47.54%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Citius Oncology has paid $696,240 in taxes.

Income Tax	696,240
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -89.35% in the last 52 weeks. The beta is -0.62, so Citius Oncology's price volatility has been lower than the market average.

Beta (5Y)	-0.62
52-Week Price Change	-89.35%
50-Day Moving Average	1.18
200-Day Moving Average	5.57
Relative Strength Index (RSI)	46.40
Average Volume (20 Days)	61,515

Short Selling Information

The latest short interest is 37,128, so 0.05% of the outstanding shares have been sold short.

Short Interest	37,128
Short Previous Month	22,886
Short % of Shares Out	0.05%
Short % of Float	0.67%
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-22.38M
Pretax Income	n/a
Net Income	-23.08M
EBITDA	n/a
EBIT	-22.38M
Earnings Per Share (EPS)	-$0.33

Full Income Statement

Balance Sheet

The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.

Cash & Cash Equivalents	112
Total Debt	3.80M
Net Cash	-3.80M
Net Cash Per Share	-$0.05
Equity (Book Value)	41.29M
Book Value Per Share	0.58
Working Capital	-26.32M

Full Balance Sheet

Cash Flow

Operating Cash Flow	126,353
Capital Expenditures	n/a
Free Cash Flow	126,353
FCF Per Share	$0.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.32%
Shareholder Yield	-2.32%
Earnings Yield	-27.57%
FCF Yield	0.15%

Analyst Forecast

The average price target for Citius Oncology is $4.50, which is 284.62% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$4.50
Price Target Difference	284.62%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3